Literature DB >> 34117850

Application of molecular probes in nuclear imaging of neuroendocrine tumors.

Jing Yan1, Tingting Zhang1, Kui Zhao1.   

Abstract

Neuroendocrine tumors are a type of heterogeneous tumors originating from neuroendocrine cells derived from the neural crest,which can secrete a variety of amines and peptide hormones.Based on different molecular biomarkers,histologic types and differentiation degrees,individualized nuclear imaging can provide information for the early diagnosis,clinical staging,treatment guidance,and detection of the recurrence and metastasis of neuroendocrine tumor. In this paper,we review the development and application of nuclear medicine molecular imaging probes such as glucose analogs,somatostatin analogues,amine precursors,hormone analogs and enzyme inhibitors in the diagnosis and treatment of neuroendocrine tumors.

Entities:  

Keywords:  Diagnosis; Molecular probe; Neuroendocrine tumors; Nuclear medicine imaging; Review

Mesh:

Substances:

Year:  2021        PMID: 34117850      PMCID: PMC8675064          DOI: 10.3724/zdxbyxb-2021-0031

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  29 in total

Review 1.  Role of PET/CT in the functional imaging of endocrine pancreatic tumors.

Authors:  Vittoria Rufini; Richard P Baum; Paola Castaldi; Giorgio Treglia; Anna Maria De Gaetano; Cecilia Carreras; Daniel Kaemmerer; Merten Hommann; Dieter Hörsch; Lorenzo Bonomo; Alessandro Giordano
Journal:  Abdom Imaging       Date:  2012-12

2.  18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.

Authors:  Margot Bucau; Astrid Laurent-Bellue; Nicolas Poté; Olivia Hentic; Jérôme Cros; Nidaa Mikail; Vinciane Rebours; Philippe Ruszniewski; Rachida Lebtahi; Anne Couvelard
Journal:  Neuroendocrinology       Date:  2017-08-11       Impact factor: 4.914

3.  Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?

Authors:  Duygu Has Simsek; Serkan Kuyumcu; Cuneyt Turkmen; Yasemin Sanlı; Faruk Aykan; Seher Unal; Isik Adalet
Journal:  J Nucl Med       Date:  2014-10-14       Impact factor: 10.057

4.  Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography.

Authors:  H Orlefors; A Sundin; L Lu; K Oberg; B Långström; B Eriksson; M Bergström
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-24       Impact factor: 9.236

5.  Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.

Authors:  Saila Kauhanen; Camilla Schalin-Jäntti; Marko Seppänen; Sami Kajander; Sami Virtanen; Jukka Schildt; Irina Lisinen; Aapo Ahonen; Ilkka Heiskanen; Mika Väisänen; Johanna Arola; Pirkko Korsoff; Tapani Ebeling; Timo Sane; Heikki Minn; Matti J Välimäki; Pirjo Nuutila
Journal:  J Nucl Med       Date:  2011-11-03       Impact factor: 10.057

6.  The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer.

Authors:  A Zer; L Domachevsky; Y Rapson; M Nidam; D Flex; A M Allen; S M Stemmer; D Groshar; H Bernstine
Journal:  Eur Radiol       Date:  2015-12-18       Impact factor: 5.315

Review 7.  Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

Authors:  Martijn van Essen; Anders Sundin; Eric P Krenning; Dik J Kwekkeboom
Journal:  Nat Rev Endocrinol       Date:  2013-12-10       Impact factor: 43.330

Review 8.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

9.  Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.

Authors:  Vikas Prasad; Valentina Ambrosini; Merten Hommann; Dieter Hoersch; Stefano Fanti; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

10.  18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.

Authors:  Alessio Imperiale; Edmond Rust; Sophie Gabriel; Julien Detour; Bernard Goichot; Bernard Duclos; Jean-Emmanuel Kurtz; Philippe Bachellier; Izzie-Jacques Namer; David Taïeb
Journal:  J Nucl Med       Date:  2013-12-16       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.